AbbVie and Gedeon Richter Plc. ('Richter') today announced a new discovery, co-development and license agreement to advance novel targets for the potential treatment of neuropsychiatric conditions.

According to a new comprehensive report from The Insight Partners, the global biologics market is expected to reach U.S.$ ...

Inc. (Nasdaq: IXHL), (Incannex), a clinical-stage biopharmaceutical company developing innovative medicines for people with chronic diseases and significant unmet medical needs, today announced the ...

The U.S. stock market has performed very well overall in the past five years. But nearly 38% of individual stocks are down in ...

NEW YORK and MELBOURNE, Australia, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex), a clinical ... and operational roles at Jazz Pharmaceuticals, AbbVie, Biogen, ...

Analyst Alec Stranahan of Bank of America Securities maintained a Hold rating on Alector (ALEC – Research Report), retaining the price ...

Merck & Co., Inc., Sanofi S.A., Johnson & Johnson, AbbVie Inc., Bristol-Myers Squibb Company, and Roche Holding AG are ...

AbbVie (ABBV) and Gedeon Richter announced a new discovery, co-development and license agreement to advance novel targets for the potential ...

Vyalev, also known as Produodopa, has been approved in 35 countries, with more than 4200 patients having started treatment.

The abrdn Total Dynamic Dividend Fund offers a high yield, outperforms major indices, and focuses on dividend-paying equities ...

DelveInsight's Protein Chip Market Insights report provides the current and forecast market analysis, individual leading protein ...

Healthcare ETFs are an ideal investment choice for investors as they provide favorable returns, diversification, and robust ...